Geographical and Epidemiological Characteristics of Sporadic
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Current and Future Natural Gas Demand in China and India
Global Gas/LNG Research Current and Future Natural Gas Demand in China and India By Miranda Wainberg Senior Energy Advisor Michelle Michot Foss, Ph.D. Chief Energy Economist and Program Manager Gürcan Gülen, Ph.D. Senior Energy Economist and Research Scientist Daniel Quijano Economist and Research Associate April 2017 April 2017, BEG/CEE China/India Gas Demand, Page 1 TABLE OF CONTENTS ESSENTIAL ACRONYMNS, UNITS AND CONVERSIONS ................................................................................................... 5 ACKNOWLEDGMENTS .................................................................................................................................................... 6 PREFACE ......................................................................................................................................................................... 7 INTRODUCTION ............................................................................................................................................................. 8 MACROECONOMIC CONTEXT FOR NATURAL GAS IN CHINA AND INDIA ...................................................................... 9 Composition of GDP and Employment Structure ...................................................................................................... 9 GDP Growth and Industrial Structures in China and India ...................................................................................... 11 Industrial overcapacity and debt in China ......................................................................................................... -
Occupational Characteristics and Management Measures of Sporadic
Occupational characteristics and management measures of sporadic COVID-19 outbreaks from June 2020 to January 2021 in China: the importance of tracking down “patient zero” Maohui Feng 1,a, Qiong Ling 2,a, Jun Xiong 3, Anne Manyande 4, Weiguo Xu 5, Boqi Xiang 6,* 1 Department of Gastrointestinal Surgery, Wuhan Peritoneal Cancer Clinical Medical Research Center, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan 430071, Hubei, PR China; 2 Department of Anesthesiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong, PR China; 3 Hepatobiliary Surgery Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; 4 School of Human and Social Sciences, University of West London, London, United Kingdom; 5 Department of Orthopedics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR China; 6 School of Public Health, University of Rutgers, New Brunswick, NJ 08854, USA. a These authors have contributed equally to this work. *Correspondence: Boqi Xiang, E-mail: [email protected] Abstract There are occupational disparities in the risk of contracting COVID-19. Occupational characteristics and work addresses play key roles in tracking down “patient zero”. The present descriptive analysis for occupational characteristics and management measures of sporadic COVID-19 outbreaks from June to December 2020 in China offers important new information to the international community at this stage of the pandemic. These data suggest that Chinese measures including tracking down “patient zero”, launching mass COVID-19 testing in the SARS-CoV-2-positive areas, designating a new high or medium-risk area, locking down the corresponding community or neighborhood in response to new COVID-19 cases and basing individual methods of protection on science, are effective in reducing transmission of the highly contagious SARS-CoV-2 across China. -
Innovent Biologics (1801
22 Jul 2021 CMB International Securities | Equity Research | Company Initiation Innovent Biologics (1801 HK) BUY (Initiation) Growing into a global biopharma company Target Price HK$120.91 Up/Downside +43.00% Current Price HK$84.55 Rich innovative drug pipelines. Innovent is a leading integrated biopharma company with comprehensive innovative pipelines including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), small molecules and CAR- China Healthcare Sector T therapies, covering oncology, autoimmune and metabolic diseases. Besides five marketed products (sintilimab, three biosimilars and pemigatinib), Jill Wu, CFA Innovent has six innovative drugs in pivotal clinical stage, including IBI306 (852) 3900 0842 (PCSK9 antibody), IBI310 (CTLA-4 antibody), IBI376 (PI3Kδ inhibitor), IBI326 [email protected] (BCMA-CART), taletrectinib (ROS1/NTRK inhibitor) and HQP1351 (olverembatinib, third-generation BCR-ABL TKI). In addition, Innovent has Sam Hu, PhD established a comprehensive innovative portfolio covering next-generation (852) 3900 0882 immuno-oncology (I/O) targets, including CD47/SIRPα, TIGT, LAG3, 4-1BB, [email protected] etc. It’s worth noting that Innovent is an early mover in CD47-SIRPα pathway with three assets under development, including clinical-stage IBI188 (a CD47 Jonathan Zhao antibody) and IBI322 (a PD-L1/CD47 bispecific antibody), and preclinical (852) 6359 1614 stage IBI397 (AL008, a SIRPα antibody). [email protected] Tyvyt being an early mover in large indications. After the approval for r/r- cHL in Dec 2018, Tyvyt has been approved by the NMPA for 1L ns-NSCLC, Mkt. Cap. (HK$ mn) 123,312 1L s-NSCLC and 1L HCC in 2021. These three large indications may be Avg. -
Recent Articles from the China Journal of System Engineering Prepared
Recent Articles from the China Journal of System Engineering Prepared by the University of Washington Quantum System Engineering (QSE) Group.1 Bibliography [1] Mu A-Hua, Zhou Shao-Lei, and Yu Xiao-Li. Research on fast self-adaptive genetic algorithm and its simulation. Journal of System Simulation, 16(1):122 – 5, 2004. [2] Guan Ai-Jie, Yu Da-Tai, Wang Yun-Ji, An Yue-Sheng, and Lan Rong-Qin. Simulation of recon-sat reconing process and evaluation of reconing effect. Journal of System Simulation, 16(10):2261 – 3, 2004. [3] Hao Ai-Min, Pang Guo-Feng, and Ji Yu-Chun. Study and implementation for fidelity of air roaming system above the virtual mount qomolangma. Journal of System Simulation, 12(4):356 – 9, 2000. [4] Sui Ai-Na, Wu Wei, and Zhao Qin-Ping. The analysis of the theory and technology on virtual assembly and virtual prototype. Journal of System Simulation, 12(4):386 – 8, 2000. [5] Xu An, Fan Xiu-Min, Hong Xin, Cheng Jian, and Huang Wei-Dong. Research and development on interactive simulation system for astronauts walking in the outer space. Journal of System Simulation, 16(9):1953 – 6, Sept. 2004. [6] Zhang An and Zhang Yao-Zhong. Study on effectiveness top analysis of group air-to-ground aviation weapon system. Journal of System Simulation, 14(9):1225 – 8, Sept. 2002. [7] Zhang An, He Sheng-Qiang, and Lv Ming-Qiang. Modeling simulation of group air-to-ground attack-defense confrontation system. Journal of System Simulation, 16(6):1245 – 8, 2004. [8] Wu An-Bo, Wang Jian-Hua, Geng Ying-San, and Wang Xiao-Feng. -
World Energy Investment 2021 INTERNATIONAL ENERGY AGENCY
World Energy Investment 2021 INTERNATIONAL ENERGY AGENCY The IEA examines the IEA member IEA association full spectrum countries: countries: of energy issues including oil, gas and Australia Brazil coal supply and Austria China demand, renewable Belgium India energy technologies, electricity markets, Canada Indonesia energy efficiency, Czech Republic Morocco access to energy, Denmark Singapore demand side Estonia South Africa management and Finland Thailand much more. Through France its work, the IEA Germany advocates policies that Greece will enhance the Hungary reliability, affordability Ireland and sustainability of Italy energy in its 30 member countries, Japan 8 association countries Korea and beyond. Luxembourg Mexico Netherlands New Zealand Norway Poland Portugal Please note that this Slovak Republic publication is subject to Spain specific restrictions that limit its use and distribution. The Sweden terms and conditions are Switzerland available online at Turkey www.iea.org/t&c/ United Kingdom United States This publication and any map included herein are The European without prejudice to the Commission also status of or sovereignty over participates in the any territory, to the delimitation of international work of the IEA frontiers and boundaries and to the name of any territory, city or area. Source: IEA. All rights reserved. International Energy Agency Website: www.iea.org World Energy Investment 2021 Abstract Abstract This year’s edition of the World Energy Investment report presents the latest data and analysis of how energy investment flows are recovering from the shock of the Covid-19 pandemic, including full-year estimates of the outlook for 2021. It examines how investors are assessing risks and opportunities across all areas of fuel and electricity supply, efficiency and research and development, against a backdrop of a recovery in global energy demand as well as strengthened pledges from governments and the private sector to address climate change. -
Global Offering
蘇州貝康醫療股份有限公司 SUZHOU BASECARE MEDICAL CORPORATION LIMITED (A joint stock company incorporated in the People's Republic of China with limited liability) Stock Code: 2170 GLOBAL OFFERING Sole Sponsor, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers Joint Bookrunners and Joint Lead Managers Joint Lead Manager IMPORTANT IMPORTANT: If you are in any doubt about any of the contents of this prospectus, you should seek independent professional advice. Suzhou Basecare Medical Corporation Limited 蘇州貝康醫療股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) GLOBAL OFFERING Number of Offer Shares under : 66,667,000 H Shares (subject to the the Global Offering Over-allotment Option) Number of Hong Kong Offer Shares : 6,667,000 H Shares (subject to adjustment) Number of International Offer Shares : 60,000,000 H Shares (subject to adjustment and the Over-allotment Option) Maximum Offer Price : HK$27.36 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong Dollars and subject to refund) Nominal Value : RMB1.00 per H Share Stock Code : 2170 Sole Sponsor, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers Joint Bookrunners and Joint Lead Managers Joint Lead Manager Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus. -
WHO-Convened Global Study of Origins of SARS-Cov-2: China Part
WHO-convened Global Study of Origins of SARS-CoV-2: China Part Joint WHO-China Study 14 January-10 February 2021 Joint Report 1 LIST OF ABBREVIATIONS AND ACRONYMS ARI acute respiratory illness cDNA complementary DNA China CDC Chinese Center for Disease Control and Prevention CNCB China National Center for Bioinformation CoV coronavirus Ct values cycle threshold values DDBJ DNA Database of Japan EMBL-EBI European Molecular Biology Laboratory and European Bioinformatics Institute FAO Food and Agriculture Organization of the United Nations GISAID Global Initiative on Sharing Avian Influenza Database GOARN Global Outbreak Alert and Response Network Hong Kong SAR Hong Kong Special Administrative Region Huanan market Huanan Seafood Wholesale Market IHR International Health Regulations (2005) ILI influenza-like illness INSD International Nucleotide Sequence Database MERS Middle East respiratory syndrome MRCA most recent common ancestor NAT nucleic acid testing NCBI National Center for Biotechnology Information NMDC National Microbiology Data Center NNDRS National Notifiable Disease Reporting System OIE World Organisation for Animal Health (Office international des Epizooties) PCR polymerase chain reaction PHEIC public health emergency of international concern RT-PCR real-time polymerase chain reaction SARI severe acute respiratory illness SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 SARSr-CoV-2 Severe acute respiratory syndrome coronavirus 2-related virus tMRCA time to most recent common ancestor WHO World Health Organization WIV Wuhan Institute of Virology 2 Acknowledgements WHO gratefully acknowledges the work of the joint team, including Chinese and international scientists and WHO experts who worked on the technical sections of this report, and those who worked on studies to prepare data and information for the joint mission. -
AHEC Market Report
American Hardwood Export Council Southeast Asia & Greater China January 2021 MARKET REPORT Southeast Asia & Greater China Contents Economy Grows Modestly in GRCH & • Economy Grows SEA Modestly in GRCH & SEA..............................1-4 Good news for hardwood exporters: China and Vietnam are among the first major economies to show recovery from the disruption caused by the • Market Update........4-7 Covid-19 pandemic in 2020. According to the National Bureau of Statistics • Upcoming Events in of China, the Manufacturing PMI in November 2020 was 52.1, up from 51.4 in October to its highest since March 2020, showing China’s manufacturing 2021.............................8 activity extend its strong growth. Vietnam is one of the very few countries in South East Asia to post a GDP growth during the pandemic, as the country’s production grew at 2.5-3% for the whole year of 2020. US Hardwood Exports Value (USD million) 4,000.0 3,693.6 3,665.1 3,500.0 3,290.3 2,825.0 3,000.0 2,528.6 2,500.0 2,000.0 304.5 341.4 272.2 1,500.0 361.6 342.3 1,000.0 1,949.2 1,841.6 1,556.8 500.0 1,096.4 1,076.7 - 2016 (Jan-Nov) 2017 (Jan-Nov) 2018 (Jan-Nov) 2019 (Jan-Nov) 2020 (Jan-Nov) Greater China SEA World Total Hardwood Lumber % change Hardwood Log % change Hardwood Veneer % change Greater China $727.1 million -2.7% $342.2 million 0.3% $4.74 million -2.7% Vietnam $208.3 million -1% $59.4 million -15% $6.4 million -3% Indonesia $17.7 million -9% $1.1 million -53% $7.2 million 5% Thailand $15.9 million 1% $2.1 million 179% $0.057million 47% Malaysia $13.7 million -6% $0.83 million -41% $5.6 million 12% Philippines $0.75 million -36% $0 million -- $1.16 million -33% Singapore $0.129 million -75% $0.065 million -74% $0.328 million -27% Year-on-Year changes in U.S. -
Securities and Exchange Commission Washington, D.C
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-35210 HC2 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 54-1708481 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 450 Park Avenue, 29th Floor, New York, NY 10022 (Address of principal executive offices) (Zip Code) (212) 235-2690 (Registrant’s telephone number, including area code) _____________________________________________________________________________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share HCHC New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. -
Master Question List for COVID-19 (Caused by SARS-Cov-2) Weekly Report 18 March 2020
DHS SCIENCE AND TECHNOLOGY Master Question List for COVID-19 (caused by SARS-CoV-2) Weekly Report 18 March 2020 For comments or questions related to the contents of this document, please contact the DHS S&T Hazard Awareness & Characterization Technology Center at [email protected]. DHS Science and Technology Directorate | MOBILIZING INNOVATION FOR A SECURE WORLD CLEARED FOR PUBLIC RELEASE REQUIRED INFORMATION FOR EFFECTIVE INFECTIOUS DISEASE OUTBREAK RESPONSE SARS-CoV-2 (COVID-19) Updated 3/18/2020 FOREWORD The Department of Homeland Security (DHS) is paying close attention to the evolving Coronavirus Infectious Disease (COVID-19) situation in order to protect our nation. DHS is working very closely with the Centers for Disease Control and Prevention (CDC), other federal agencies, and public health officials to implement public health control measures related to travelers and materials crossing our borders from the affected regions. Based on the response to a similar product generated in 2014 in response to the Ebolavirus outbreak in West Africa, the DHS Science and Technology Directorate (DHS S&T) developed the following “master question list” that quickly summarizes what is known, what additional information is needed, and who may be working to address such fundamental questions as, “What is the infectious dose?” and “How long does the virus persist in the environment?” The Master Question List (MQL) is intended to quickly present the current state of available information to government decision makers in the operational response to COVID-19 and allow structured and scientifically guided discussions across the federal government without burdening them with the need to review scientific reports, and to prevent duplication of efforts by highlighting and coordinating research. -
Demand for Storage and Import of Natural Gas in China Until 2060: Simulation with a Dynamic Model
sustainability Article Demand for Storage and Import of Natural Gas in China until 2060: Simulation with a Dynamic Model Zhihua Chen * , Hui Wang, Tongxia Li and Ieongcheng Si The Belt and Road School, Beijing Normal University, Beijing 100875, China; [email protected] (H.W.); [email protected] (T.L.); [email protected] (I.S.) * Correspondence: [email protected] Abstract: China has been reforming its domestic natural gas market in recent years, while construc- tion of storage systems is lagging behind. As natural gas accounts for an increasing proportion due to the goal of carbon neutrality, large-scale gas storage appears to be necessary to satisfy the needs for gas peak shaving and national strategic security. Additionally, the domestic gas production in China cannot meet consumption demands, and imports will play a significant role on the supply side. This paper developed a system dynamics (SD) model and applied it to simulate gas market behaviors and estimated China’s gas storage capabilities and import demands over the next 40 years. To achieve carbon neutrality, it is necessary for China to make great progress in its energy intensity and improve its energy structure, which have a great impact on natural gas consumption. Thus, alternative scenarios were defined to discuss the changes in the gas market with different gas storage goals and environmental constraints. The results show that under low and medium carbon price scenarios, natural gas demand will continue to grow in the next 40 years, but it will be difficult to achieve the goal of carbon neutrality. -
Shanghai Junshi Biosciences Co., Ltd
IMPORTANT IMPORTANT: If you are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) GLOBAL OFFERING Total number of Offer Shares under the : 158,910,000 H Shares (subject to the Global Offering Over-allotment Option) Number of Hong Kong Offer Shares : 15,892,000 H Shares (subject to adjustment) Number of International Placing Shares : 143,018,000 H Shares (subject to adjustment and the Over-allotment Option) Offer Price : Not more than HK$20.38 per H Share and expected to be not less than HK$19.38 per H Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong Dollars, subject to refund) Nominal value : RMB1.00 per H Share Stock code : 1877 Sole Sponsor and Lead Global Coordinator Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers Joint Bookrunners and Joint Lead Managers Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus. A copy of this prospectus, having attached thereto the documents specified in “Documents Delivered to the Registrar of Companies and Available for Inspection – Documents Delivered to the Registrar of Companies in Hong Kong” in Appendix VI to this prospectus, has been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong).